Role and management of coagulation disorders in peripheral arterial disease

Scandinavian Journal of Surgery

Volumn 101, Issue 2, 2012, Pages 94-99

  Lassila, R ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antithrombotic therapy; Arterial thrombosis; Atherothrombosis; Coagulation disorders; Peripheral arterial disease; Thrombophilia

Indexed keywords

EID: 84863734330     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749691210100204     Document Type: Review

References (24)

1. de Moerloose P, Boehlen F: Inherited thrombophilia in arterial disease-a selective review. Semin Hematol 2007;44:106-114
2. Salmela B, Albäck A, Räike P, Lepäntalo M, Lassila R: A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia. thromb Res 2009;123:719-723
3. Haapaniemi E, Helenius J, Jakovljevic D et al: Ischemic stroke patients with heterozygous Factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease. thromb Haemost 2009;101:145-150
4. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan tE, Vos HL: A common prothrombin variant (20210 g to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-1750
5. Burns PJ, Mosquera DA, Bradbury AW: Prevalence and significance of thrombophilia in peripheral arterial disease. Eur J Vasc Endovasc Surg 2001;22:98-106
6. Böhm g, Al-Khaffaf H: thrombophilia and arterial disease. An up-to-date review of the literature for the vascular surgeon. Int Angiol 2003;2:116-124
7. Sartori M, Conti E, Favaretto E, Frascaro M, Legnani C, Palareti g: thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. Eur J Vasc Endovasc Surg 2011;42:817-823
8. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809
9. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V: Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler thromb 1993;13:1738-1742
10. tschopl M, tsakiris DA, Marbet gA, Labs KH, Jäger K: Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler thromb Vasc Biol 1997;17:3208-3214
11. Rudofsky g, Strubel g, Michler E, Kuegler C, Biro F: Influence of fibrinogen and hematocrit on the early outcome of angioplasty in patients with PAOD. J Endovasc ther 2004;11:125-131
12. Kauhanen P, Beer JH, Lassila R: Defective interaction between von Willebrand factor and platelet glycoprotein Ib-a familial study of peripheral arterial occlusive disease. thromb Haemost 1997;77:849-855
13. Mustonen P, Lepäntalo M, Lassila R: Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. Arterioscler thromb Vasc Biol 1998; 18:244-249
14. Peltonen S, Lassila R, Rossi P, Salenius JP, Lepäntalo M: Blood coagulation and fibrinolysis activation during sudden arterial occlusion of lower extremities-an association with ischemia and patient outcome. thromb Haemost 1995;74:1442-1446
15. Kauhanen P, Sirén V, Carpén O, Vaheri A, Lepäntalo M, Lassila R: Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure. Circulation 1997;96:1783-1789
16. Diehm n, Schmidli J, Setacci C et al: Chapter III: Management of cardiovascular risk factors and medical therapy. Eur J Vasc Endovasc Surg 2011;42:S33-S42
17. Lassila R, Lepäntalo M: Cigarette smoking and peripheral arterial disease. Acta Chir Scand 1988;154:635-640
18. Sobel M, Verhaeghe R: Antithrombotic therapy for Peripheral Artery Occlusive Disease, American College of Chest Physicians Evidence-Based Clinical Practice guidelines (8th Edition). Chest 2008;133:815-843
19. Belch JJ, Dormandy J, Biasi gM, et al: Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825-833
20. Lepäntalo A, Virtanen K, Heikkilä J, Wartiovaara U, Lassila R: Limited antiplatelet effect of combined ASA and clopidogrel in patients undergoing elective PtCA. Eur Heart J 2004;25:476-483. Editorial: pages 454-456
21. Verkleij CJ, nieuwdorp M, gerdes VE, Mörgelin M, Meijers JC, Marx PF: the effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. thromb Haemost 2009;102:460-468
22. Salmela B, Joutsi-Korhonen L, Lassila R: Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. thromb Res 2010;125:538-544
23. Puurunen M, Lassila R: Successful treatment of mesenterial venous thrombosis with lepirudin-a report of five cases. thromb Res 2006;118:241-245
24. Salmela B, nordin A, Vuoristo M, Mäkisalo H, numminen K, Lassila R: Budd-Chiari syndrome in a young female with aPC resistance-treatment with a direct thrombin inhibitor lepirudin. Brief communication. thromb Res 2007;121:769-772